Lacerta Therapeutics Expands Executive Leadership Team
UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.
RTI Surgical: Plant Director’s Passion and Engagement Inspires Team
A passion to find a position with a company that directly impacts people’s lives led Catisha Turner to join UF startup RTI Surgical, after serving in the United States Navy for six years.
Cannabix Technologies Presents FAIMS Marijuana Breathalyzer Technology at the Texas Impaired Driving Forum
UF startup Cannabix Technologies Inc., presented key innovations for first-of-its-kind marijuana breath detection technology. This comes at a time when legislators are grappling with the ever-increasing problem of drugged driving.
Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine
UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
Fitness App FitOn Raises $40M, Acquires Corporate Wellness Platform Peerfit
Digital fitness and wellness company FitOn has raised $40 million in Series C funding led by Delta-v Capital, the company announced on Tuesday. FitOn is also expanding its reach in wellness by acquiring Tampa-based corporate wellness platform Peerfit, a UF startup that incubated at UF Innovate | Accelerate at The Hub.
National Resilience Snares Takeda Plasma Development and Manufacturing Deal
Resilience has clinched a deal to chip in on development and manufacturing of “multiple” products in Takeda’s plasma-derived therapies portfolio.
GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch
Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years.
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
The U.S. Department of Defense (DOD) has awarded UF startup Ology Bioservices, Inc. (Ology), a wholly-owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
Midwestern Higher Education Compact Enters Agreement with TAO Connect to Offer Accessible Mental Health and Wellness Resources to University Students
The agreement with TAO Connect will provide students, faculty and staff at Midwestern institutions with 24/7, free online access to over 150 self-guided digital sessions on anxiety, depression, substance abuse and more.
TearClear Announces Initiation of TC-002 Latanoprost Ophthalmic Solution Phase 3 Trial
TearClear has announced the TC-002 phase 3 trial has been successfully initiated. TearClear’s phase 3 trial (CLEAR Study) is a prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution (TearClear Preservative-Free Latanoprost Ophthalmic Solution 0.005%) compared to marketed Latanoprost ophthalmic solution 0.005%.